The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing
Zambarda et al.
SITC 2021
Zambarda et al.
SITC 2021
Pahl et al.
AACR-NCI-EORTC 2021 - AFM24
Wingert et al.
mAbs 2021; 13(1): 1950264
Kerbauy et al.
Clinical Cancer Research; 27: 3744-3756.
Pahl et al.
AACR 2021 - AFM24
Bartlett et al.
Blood 2020; 136: 2401–2409.
Reusch et al.
AACR 2020 - AFM24
Harstrick et al.
ASCO 2020 - AFM13
Ellwanger et al.
NK2019 - ROCK®
Marin et al.
NK2019 - AFM13